🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide MASH Phase 2b — 6 month update Page 4

Survodutide MASH Phase 2b — 6 month update

fiona_VT Sun, Dec 29, 2024 at 7:41 AM 16 replies 1,805 viewsPage 4 of 4
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Jan 4, 2025 at 4:40 AM#16

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

9 7jennifer_SEA, tyler_CSCS, VanRx_Mike and 6 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Jan 4, 2025 at 4:31 PM#17

One thing that is still open after steve_okc’s answer:

What would you measure differently if you were starting again?

Last edited: Jan 4, 2025 at 7:31 PM
10 8hannah_MT, Dr.SportsMedIN, amy_econ_NJ and 7 others
Reply Quote Save Share Report
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Jan 5, 2025 at 4:22 AM#18
KevinCompounds said:
The useful move here is to separate what is established from what is widely repeated.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

11 9PharmD_Rodriguez, julia.endo, JessicaM_2024 and 8 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Jan 5, 2025 at 4:13 PM#19
KevinCompounds said:
The useful move here is to separate what is established from what is widely repeated.

That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.

12 10KevinCompounds, TirzTom, TrialTracker_MD and 9 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jan 6, 2025 at 4:03 AM#20

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.

34 7PurityPaulOR, MaxMetOK, MounjBrad and 31 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register